Vorinostat is a potent histone deacetylase inhibitor that blocks the catalytic site of these
enzymes. A large number of cellular proteins are modified post-translationally by acetylation …

Histone acetylation is a posttranslational modification that plays a role in regulating gene
expression. More recently, other nonhistone proteins have been identified to be acetylated …

Medulloblastomas are the most common malignant brain tumors in childhood. Emerging
evidence suggests that medulloblastoma comprises at least four distinct diseases (WNT …

Brain cancers are the leading cause of cancer-related deaths in children. Biological
changes in these tumors likely include epigenetic deregulation during embryonal …

Medulloblastoma (MB) is a highly malignant childhood tumor of the cerebellum.
Transcriptional and epigenetic signatures have classified MB into four molecular subgroups …

Increasing evidence suggests that alterations in epigenetic mechanisms regulating
chromatin state play a role in the pathogenesis of medulloblastoma (MB), the most common …

Members of the histone deacetylase (HDAC) family exhibit great promise as potential drug
targets in pediatric tumors including neuroblastoma, medulloblastoma, ependymoma and …

Histone deacetylase inhibitors (HDACis) have fascinated researchers in almost all fields of
oncology for many years owing to their pleiotropic effects on nearly every aspect of cancer …

Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in
childhood. Despite the advances in treatment, about 20% of patients relapse and/or die …

Histone deacetylase (HDAC) inhibitor treatments can augment the anti-tumor effects of
retinoids in renal cancer cells. We studied the effects of the HDAC inhibitor suberoylanilide …